Blood graft composition after plerixafor injection in patients with NHL

European Journal of Haematology

Volumn 89, Issue 2, 2012, Pages 128-135

  Varmavuo, Ville ^a   Mäntymaa, Pentti ^b   Nousiainen, Tapio ^a   Valonen, Piia ^c   Kuittinen, Taru ^a   Jantunen, Esa ^a,c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b Cancer Center of Eastern Finland   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

CD34+ subclasses; Engraftment; Lymphocyte subsets; Lymphoma; Outcome; Plerixafor; Viability

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; MALE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL MOBILIZATION; SUPPRESSOR CELL; THROMBOCYTE COUNT;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 84863855443     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01794.x     Document Type: Article

References (29)

1. Appelbaum FR. Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow. J Clin Oncol 2008;26:2927-9.
2. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, Frauendorfer K European Group for Blood and Marrow Transplantation EBMT. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011;46:485-501.
3. Jantunen E, Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol 2010;85:463-71.
4. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867-74.
5. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45:39-47.
6. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G. AMD3100 plus G-CSF can successfully mobilize CD34 + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008;41:331-8.
7. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011;46:523-8.
8. Horwitz ME, Chute JP, Gasparetto C, Long GD, McDonald C, Morris A, Rizzieri DA, Sullivan KM, Chao NJ. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant 2011;November 14 Epub.
9. Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012;52:55-62.
10. D'Addio A, Curti A, Worel N et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011;46:356-63.
11. Jantunen E, Kuittinen T, Mahlamäki E, Pyörälä M, Mäntymaa P, Nousiainen T. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011;86:299-304.
12. Jantunen E, Lemoli RM. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 2012;52:906-14.
13. Fruehauf S, Tricot G. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes. Biol Blood Marrow Transplant 2010;16:1629-48.
14. Jantunen E, Fruehauf S. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant 2011;46:627-35.
15. + hematopoietic cells from normal volunteers stimulated with granulocyte-colony-stimulating factor by a single-dose of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295-300.
16. + cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulation factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007;16:657-66.
17. Gazitt Y, Shaughnessy P, Devore P. Mobilization of dendritic cells and NK cell in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001;10:117-86.
18. Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA, Johnston PB, Gastineau DA, Markovic SN. AMD3100 affects autograft lymphocyte collection and progression-free survival in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007;7:315-8.
19. Porrata LF, Litzow MR, Inwards DJ et al. Infused peripheral blood autograft lymphocyte count correlated with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:291-8.
20. Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T, Jantunen E. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Transfusion 2012;February 5 Epub.
21. Fruehauf S, Veldwijk MR, Seeger T et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009;11:992-1001.
22. Taubert I, Saffrich R, Zepeda-Moreno A, Hellwig I, Eckstein V, Bruckner T, Ho AD, Wuchter P. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. Cytotherapy 2011;13:459-66.
23. Zubair AC, Kao G, Daley H, Schott D, Freedman A, Ritz J. CD34(+)CD38(-) and CD34(+)HLA-DR(-) cells in BM stem cell grafts correlated with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy 2006;8:399-407.
24. Porrata LF, Gastineau DA, Padley D, Bundy K, Markovic SN. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003;44:997-1000.
25. Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008;14:116-24.
26. + lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation. Am J Hematol 2009;84:21-8.
27. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-9.
28. Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT, Bolwell BJ, Bridger G, Marulkar S, Hsu FJ, DiPersio JF. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 2011;17:1146-53.
29. Morris C, Sureda A, van Biezen A, Mohty M, Ljungman P, Iacobelli S, Boumendil A, Basak G, Dreger P, de Witte T on behalf of the Chronic Leukaemia and Lymphoma Working Parties of EBMT. The EMA-directed plerixafor safety survey: the EBMT CALM study. Bone Marrow Transplant 2011;46 (Suppl.1):S32 (abstr. 244).